Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology · 2026
All-cause mortality benefits of attending phase 3 cardiac rehabilitation: A systematic review.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aguiar-Ricardo Inês, Inácio Cazeiro Daniel, Alves da Silva Pedro, Sena Silva Catarina, Abrantes Ana, Cunha Nelson, Clarissa Rodrigues Maria, Cardoso Andrade Ana Rita, Pinto Rita, Caldeira Daniel, Pinto Fausto J, Abreu Ana
Аннотация
AIM: The primary objective of this study was to assess the impact of attending a phase 3 cardiac rehabilitation (CR) program on all-cause mortality.
METHODS: We conducted a systematic review using database searches (MEDLINE and Cochrane Central Register of Controlled Trials) up to December 2022 to identify studies that compared adult patients undergoing phase 3 of CR with those receiving usual care.
RESULTS: Out of a total of 1867 identified articles, eight met the eligibility criteria (two randomized controlled trials (RCT) and six non-RCT) and were included (n=60939 patients; 82% male, average age of 62±11 years). Phase 3 of a CR program showed a significant association with reduced mortality rates, with a hazard ratio (HR) of 0.56 (95% CI 0.49-0.65), with minimal evidence of statistical heterogeneity. The studies presented a range of differently structured CR programs. They varied in duration, training methods, and components.
CONCLUSION: This systematic review demonstrates that attending a phase 3 CR program has the beneficial effect of reducing mortality among patients with cardiovascular disease, in particular those with coronary artery disease. These findings highlight the importance of CR participation on a long-term basis and reinforce the value of increasing the number of specialized worldwide and optimizing patient referrals to participate in a long-term phase 3 CR program.
METHODS: We conducted a systematic review using database searches (MEDLINE and Cochrane Central Register of Controlled Trials) up to December 2022 to identify studies that compared adult patients undergoing phase 3 of CR with those receiving usual care.
RESULTS: Out of a total of 1867 identified articles, eight met the eligibility criteria (two randomized controlled trials (RCT) and six non-RCT) and were included (n=60939 patients; 82% male, average age of 62±11 years). Phase 3 of a CR program showed a significant association with reduced mortality rates, with a hazard ratio (HR) of 0.56 (95% CI 0.49-0.65), with minimal evidence of statistical heterogeneity. The studies presented a range of differently structured CR programs. They varied in duration, training methods, and components.
CONCLUSION: This systematic review demonstrates that attending a phase 3 CR program has the beneficial effect of reducing mortality among patients with cardiovascular disease, in particular those with coronary artery disease. These findings highlight the importance of CR participation on a long-term basis and reinforce the value of increasing the number of specialized worldwide and optimizing patient referrals to participate in a long-term phase 3 CR program.